Ebenbuild receives 2.5 million euros

The healthtech now wants to further develop its prototype for simulating the lungs and seek approval as a medical device.

Healthtech Ebenbuild has closed a seed financing round of 2.5 million euros. High-Tech Gründerfonds and Bayern Capital, the venture capital company of the Free State of Bavaria, jointly led the round. A number of business angels also invested in the start-up. Ebenebuild had already announced in February that it was about to close a financing round worth millions.

Kei Müller, Jonas Biehler, Wolfgang Wall and Karl-Robert Wichmann founded Ebenbuild in 2019, having previously conducted research at the Technical University of Munich into a better treatment for acute respiratory distress syndrome. This often occurs after other illnesses and is frequently fatal. Together, the researchers developed software that creates simulation models of lungs based on patient data. With the help of the simulations, doctors can then put together an individual treatment plan for their patients.

"We are convinced that after years of preparation and more than 15 years of cutting-edge international research, we can now envisage clinical use of our product," says Ebenbuild founder and CEO Kei Müller. Ebenbuild intends to use the funds from the financing round to further develop its prototype and seek approval as a medical product.